Taysha Gene Therapies, Inc. TSHA Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s current ratio?
- Taysha Gene Therapies, Inc. (TSHA) reported current ratio of 14× in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s current ratio changed year-over-year?
- Taysha Gene Therapies, Inc.'s current ratio increased by 162.4% year-over-year, from 5.4× to 14×.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s current ratio?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s current ratio has grown at a -19.5% compound annual growth rate (CAGR), from 36.2× to 12.2×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.